The development of pharmaceutical products is often expensive
and unpredictable. Researchers investing the time and resources to
develop a novel and non-obvious advancement over the art are
rewarded with patent protection. It is therefore important to
understand the framework applied by U.S. courts to determine
whether an advancement is non-obvious, and therefore
patentable.
This article examines three recent Federal Circuit
cases—Endo Pharmaceuticals Solutions, Inc. v. Custopharm
Inc., Mylan Pharmaceuticals Inc. v. Research Corporation
Technologies, Inc., and Endo Pharmaceuticals Inc. v.
Actavis LLC, demonstrating how chemical and pharmaceutical
formulation technology is highly complex and that the
unpredictability present in drug development supports the
non-obviousness of pharmaceutical patent claims.